ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08905
-0,05%
Bitcoin
66.851,57
-0,34%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AcelRX Pharmaceuticals Inc (ACRX)

  7. AcelRX Pharmaceuticals Inc (ACRX) News

ACRX

AcelRX Pharmaceuticals (ACRX)

AcelRX Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ACRX
DatumZeitQuelleÜberschriftSymbolFirma
29/04/202422h25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ACRXAcelRX Pharmaceuticals Inc
29/04/202422h24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRXAcelRX Pharmaceuticals Inc
29/04/202422h23Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACRXAcelRX Pharmaceuticals Inc
19/04/202422h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
21/03/202421h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
15/03/202421h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/03/202423h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/01/202415h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/01/202415h05PR Newswire (US)AcelRx Announces Rebranding With Name Change to Talphera, Inc.NASDAQ:ACRXAcelRX Pharmaceuticals Inc
14/12/202314h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
13/12/202322h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
13/12/202322h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/12/202314h30PR Newswire (US)AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United StatesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
01/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACRXAcelRX Pharmaceuticals Inc
22/11/202322h38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACRXAcelRX Pharmaceuticals Inc
22/11/202322h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRXAcelRX Pharmaceuticals Inc
14/11/202312h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRXAcelRX Pharmaceuticals Inc
08/11/202322h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
08/11/202322h05PR Newswire (US)AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
07/11/202322h05PR Newswire (US)AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical StudyNASDAQ:ACRXAcelRX Pharmaceuticals Inc
26/10/202322h30PR Newswire (US)AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
20/10/202322h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/10/202322h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
05/10/202322h45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRXAcelRX Pharmaceuticals Inc
05/10/202322h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
03/10/202314h30PR Newswire (US)AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration StudyNASDAQ:ACRXAcelRX Pharmaceuticals Inc
22/09/202323h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/09/202301h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
06/09/202314h30PR Newswire (US)AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment ConferenceNASDAQ:ACRXAcelRX Pharmaceuticals Inc
28/08/202312h35Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRXAcelRX Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACRX

Kürzlich von Ihnen besucht

BIT
UB1C6X
Unicredit Bank
LBNK
HOODUSDT
HOOD AI
BIT
S29608
Societe Generale Effekten
BIT
UV8CMP
UniCredit Bank
USOTC
CSJT
Changsheng (CE)
NASDAQ
LNGR
Global X Longevity Thema...
EU
LEM
Lyxor Asset Management
AMEX
KLR
Kaleyra
COIN
SLDSEUR
EU
BER0000454P6
Record Record 1.2% 10y 1...
NASDAQ
REGLX
Regnan Global Equity Imp...
COIN
HIBSUST
Hiblocks
USOTC
RDBBY
Redbubble (PK)
DBI
4N9K
DAXsubsector All Private...
NASDAQ
VTAQW
Ventoux CCM Acquisition
LSE
0RP3
Kamux Oyj
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten